Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scale aims to better track nerve disease in kids

NCT ID NCT01203085

Knowledge-focused Sponsor: University of Iowa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study created and tested a new scale called the CMT Pediatric Scale to measure symptoms and physical function in children with Charcot-Marie-Tooth disease. Researchers enrolled 500 children under 21 with CMT types 1, 2, or 4 at multiple centers. The scale assesses foot and hand symptoms, strength, sensation, balance, and motor skills to improve monitoring of the disease over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this scale could become a standard tool for tracking CMT in children, helping doctors and researchers better understand the disease and evaluate future treatments.
What could go wrong
This is an observational study to develop a measurement tool, not a treatment trial. The scale may not capture all important aspects of the disease or may need further refinement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2010

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are 21 years of age and under who are also enrolled in the 6601 study and have performed all tasks to complete the CMT Peds Scale will be recruited for participation. Participation entails allow the information collected in the 6601 study be used for validation in the current study.

Ages

Up to 21 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients MUST be seen in person at one of the participating centers for enrollment in this study. * Children (\< 21 years of age) * Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4 Exclusion Criteria: * Known diagnoses of acquired neuropathy including toxic (e. g. medication related neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory \[acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory demyelinating polyneuropathy (CIDP)\] polyneuropathies; neuropathy related to leukodystrophy, congenital muscular dystrophy; and patients with severe general medical conditions. * Entirely normal conduction velocities of upper and lower limbs as this suggests that the subject may not have a neuropathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Charcot-Marie-Tooth disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Charcot-Marie-Tooth disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Charcot-Marie-Tooth disease

Contacts and locations

Locations

  • C. Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Children's Hospital of Westmead

    Sydney, New South Wales, 2145, Australia

  • Dubowitz Neuromuscular Centre

    London, UK, United Kingdom

  • National Hospital of Neurology and Neurosurgery

    London, England, WC1N 3BG, United Kingdom

  • Nemours Children's Clinic

    Orlando, Florida, 32827, United States

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • Stanford University

    Palo Alto, California, 94305, United States

  • The Hospital for Sick Children

    Toronto, Ontario, M5G 1X8, Canada

  • University of Connecticut/Connecticut Children's Medical Center

    Hartford, Connecticut, 06106, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • University of Rochester

    Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.